Amneal Pharmaceuticals received FDA approval for its lanreotide injection, a generic equivalent to SOMATULINE Depot. The company plans an immediate commercial launch for the treatment of acromegaly and certain tumors.
The branded version generated approximately $983 million in U.S. annual sales for the twelve months ending July 2026. IQVIA data identifies this as a significant market opportunity for the company's complex injectables portfolio.
The FDA granted the product a Competitive Generic Therapy (CGT) designation to encourage development for drugs with limited competition. Amneal expects the approval to drive material growth for its Affordable Medicines business segment.